A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness

Abstract

One hundred and eighty three patients with DSM-III-R major depressive illness were allocated randomly to treatment with one of two new generation antidepressants, fluoxetine and lofepramine. Both patient groups had significantly lower mean scores on the Hamilton Depression Rating Scale (HDRS) 6 weeks after entry to the trial (p < 0.001), but there were no differences between the groups, either at baseline or after 6 weeks, in total HRDS score or in subscores for anxiety or suicidality. Anticholinergic side effects were commoner with lofepramine; adverse effects were on the whole mild and few patients dropped out because of them. This study does not support previous claims of specific adverse effects of fluoxetine on anxiety and suicidality.

Keywords

fluoxetine lofepramine comparison major depressive illness SSRI

Get full access to this article

View all access options for this article.

References

American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (3rd edn, revised). American Psychiatric Association, Washington DC

Beasley C.M. , Dornseif B.E. , Bosomworth J.C. , Sayler M.E. , Rampey A.H. , Heiligenstein J.H. , Thompson V.L. , Murphy D.J. , Masica D.N. (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br Med J 303: 685-692

Carney M W P , Roth M. , Garside R.F. (1965) The diagnosis of depressive syndromes and the prediction of ECT responses. Br J Psychiatr 11: 659-674

Cassidy S. , Henry J. (1987) Fatal toxicity of antidepressant drugs in overdose . Br Med J 295: 1021-1024

Committee on Safety of Medicines (1988) Lofepramine (Gamanil) and abnormal blood tests of liver function. Current Problems No 23

Committee on Safety of Medicines (1989) Current Problems No 26

Georgotas A. , McCue R.E. , Cooper G.L. (1989) Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatr Res 28: 1-9

Goodwin G.M. (1992) Tricyclic and newer antidepressants. In Paykel E S (ed.), Handbook of affective disorders . Churchill Livingstone, Edinburgh , pp. 327-343

Greenhouse J.B. , Kupfer D.J. , Frank E. , Jarrett DB , Rejman KA (1987) Analysis of time to stabilisation in the treatment of depression: biological and clinical correlates. J Affective Disord 13: 259-266

10.

Hamilton M. (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278-296

11.

Henry J. (1992) The safety of antidepressants. Br J Psychiatr 160: 439-441

12.

Kelly C. , Roche S. , Naguib M. et al. (1993) A prospective evaluation of the hepatotoxicity of lofepramine in the elderly. Int Clin Psychopharmacol 8: 83-86

13.

Kerihuel J.C. , Dreyfus J.F. (1991) Meta-analyses of the efficacy and tolerability of the tricyclic antidepressant lofepramine. J Int Med Res 19: 183-201

14.

Leonard B.E. (1987) A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite desipramine: a review. Int Clin Psychopharmacol 2: 281-297

15.

Montgomery S.A. , Asberg M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatr 134: 382-389

16.

Muijen M. , Roy D. , Silverstone T. , Mehmet A. , Christie M. (1988) A comparative trial of fluoxetine, mianserin and placebo with depressed out-patients. Acta Psychiatr Scand 78: 384-390

17.

Teicher M.H. , Glod C. , Cole J.O. (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatr 147: 207-210